18th International Conference on Malignant Lymphoma (ICML  2025)

June 17-21, 2025, Lugano, Switzerland

test header

Share

Hematology

ICML 2025

Lugano

Oral

BMS-986458, a first-in-class, bifunctional, cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6) in patients with relapsed/refractory non-Hodgkin lymphoma: initial phase 1 results

Franck Morschhauser, David Qualls, Jennifer Lue, Anastasios Stathis, Marcel Nijland, Noémie Lang, Jörg Bittenbring, Guillaume Cartron, Avyakta Kallam, Loïc Ysebaert, Vladan Vucinic, Jonathan Kolitz, Noelia Purroy, Bérengère de Moucheron, Alicia Benítez Rondán, Joseph Burnett, Carla Guarnios, Xiaosong Li, Michael Pourdehnad, Thomas Hueso.

U.S. Medical Information & Services

Access medical information and resources for U.S. healthcare professionals.

Medical Information Online  External new tab
Medical Information Contact Center

800-321-1335 (toll free U.S. only)

Mon - Fri, 8am - 5pm ET

Report Adverse Events or Product Quality Complaints

800-721-5072 (toll free U.S. only)

For outside the U.S., visit our global site to report Adverse Events, Product Quality Complaints or submit a Medical Information inquiry.

Follow us

      

Legal notice  External new tab

Privacy notice center  External new tab

Your Privacy Choices

Trademarks  External new tab

© 2025 Bristol-Myers Squibb Company
BMS Medical is a trademark of Bristol-Myers Squibb Company
466-US-2500229 8/25